[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"achr-myasthenia-gravis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:achr-myasthenia-gravis":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":41,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100651499","the-axis-registry-is-a-10-year-longitudinal-research-initiative-that-captures-the-real-world-experiences-of-people-living-with-autoimmune-neurology-conditions-launching-in-myasthenia-gravis-mg-we-plan-to-evaluate-expansion-to-other-conditions-across-autoimmune-neurology-100651499",false,"NCT07761026","AXIS MG Patient Registry","AXIS Autoimmune Neurology Registry","AXIS","Inclusion Criteria:\n\n* Physician-confirmed diagnosis of myasthenia gravis (MG)\n* Willing and legally able to provide consent\n* Lives in the United States\n\nExclusion Criteria:\n\n* Unwilling or unable to provide consent or comprehend and complete questionnaires\n* Cognitively impaired adults\u002Funable to comprehend or understand the consent or overall study information","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.\n\nThe main questions the registry aims to answer are:\n\n* How do symptoms, daily functioning, and quality of life change over time?\n* What treatments do participants use, and how are these treatments related to their symptoms and health?\n* What challenges do participants experience with treatment, including side effects, treatment burden, missed doses, and access to care?\n\nParticipants will:\n\n* Join the registry and complete an enrollment survey (online or through a mobile app)\n* Complete a brief online survey about their MG approximately once a month\n* Provide information that can help confirm their MG diagnosis\n* Optionally, share their medical records with the research team\n\nThis is an observational study. The registry will not assign treatments or ask participants to change their medical care. Information collected through the registry may help researchers better understand MG and improve future research and care.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Myasthenia Gravis (MG)","Myasthenia Gravis, Generalized","Myasthenia Gravis, Ocular","Myasthenia Gravis Crisis","Myasthenia Gravis Associated With Thymoma","Myasthenia Gravis Exacerbations","Myasthenia Gravis Generalised","Myasthenia Gravis Generalized","Myasthenia Gravis, Thymectomy","Myasthenia Gravis","Myasthenia Gravis, MuSK","AChR Myasthenia Gravis","AChR-Ab Seropositive Generalized Myasthenia Gravis","MG","MG - Myasthenia Gravis",[42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57],"myasthenia gravis","autoimmune diseases of the nervous system","neuromuscular junction diseases","patient registries","natural history","longitudinal studies","observational study","patient-reported outcome measures","quality of life","activities of daily living","treatment patterns","medication adherence","treatment burden","healthcare utilization","disease progression","real-world data","RECRUITING","2026-08-14",{"date":61,"type":62},"2026-08-17","ACTUAL",{"date":64,"type":62},"2026-03-19",{"date":66,"type":21},"2036-03",{"name":68,"class":69},"Autoimmune Neurology Alliance","OTHER",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":70},"100582232","phase-4-treatment-of-myasthenia-gravis-exacerbation-or-crisis-with-efgartigimod-100582232","NCT06860633","Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod","Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod: A Single Arm, Open Label Prospective Cohort Study","Inclusion Criteria:\n\n* Adults ≥ age 18 years with known generalized MG as identified by characteristic signs of generalized MG on clinical assessment and positive serology for AchR antibodies as well as one of the following:\n\n  1. Documented positive response to cholinesterase inhibitors such as pyridostigmine or edrophonium\n  2. Abnormal decrement on slow repetitive nerve stimulation testing\n  3. Abnormal single fiber EMG\n* Evidence of worsening weakness requiring hospital admission for stabilization and change in therapy as determined by a neuromuscular expert including:\n\n  1. Quantitative Myasthenia Gravis (QMG) scale ≥ 11\n  2. MG-ADL score ≥ 6\n  3. Worsening weakness that is unlikely to be ameliorated by adjustment of current medications including impaired respiratory status, dysarthria, dysphagia, difficulty chewing, limb weakness, diplopia, ptosis.\n* Ability to sign consent and be enrolled within 24 hours of hospital admission. For participants transferred to University of Colorado Hospital, the time of admission\u002Fpresentation to the outside hospital is counted towards this 24-hour cap.\n\nExclusion Criteria:\n\n* MG worsening thought to be related to active infection or due to medications (e.g. fluoroquinolone or aminoglycoside antibiotics, magnesium, chloroquine derivatives)\n* Intubation prior to ability to sign informed consent or intubation within 24 hours of hospitalization\n* Use of IVIG within 2 weeks, or having undergone plasma exchange or received efgartigimod in the 4 weeks prior to admission\n* Current ongoing use of ravulizumab or eculizumab (monoclonal antibody C5-complement inhibitors).\n* Other medical conditions that, in the opinion of the investigator and treating clinicians, might interfere with the validity of assessment measures used in the study (e.g. steroid myopathy, CNS pathology, severe arthritis, fractures, etc.). This criterion is a standard exclusion in MG trials and relates solely to other conditions that reduce muscle power or range of motion and would thus worsen scores on assessment measures like the QMG due to non-MG conditions.\n* Known history of coagulopathy, blood clotting, recent severe bleeding (e.g. GI bleed).\n* Pregnancy or breastfeeding. Pregnancy must be excluded for all potential participants who are able to become pregnant prior to initiation of treatment.\n* IgG levels \\\u003C 600mg\u002FdL\n* Evidence of active or chronic Hepatitis B infection, untreated Hepatitis C infection, HIV with low CD4 (\\\u003C200) count.",{"count":79,"type":21},20,"INTERVENTIONAL",[82],"PHASE4","This study plans to learn more about if the drug efgartigimod can be used in the hospital to treat exacerbations in participants with myasthenia gravis (MG). Efgartigimod has been approved by the FDA for ongoing (chronic) treatment of generalized MG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive but has not been studied in the treatment of worsening weakness requiring hospital admission (known as \"exacerbation\"). This investigation aims to see if using efgartigimod in this way improves symptoms and recovery from exacerbation, and how it affects certain MG markers in the blood. The main questions it aims to answer are:\n\n* Is efgartigimod effective as a hospital-administered acute therapy for participants with worsening MG (MG exacerbation) who require hospitalization?\n* Will efgartigimod lead to clinical improvement with a similar reduction in validated research scales, such as the Quantitative MG (QMG) scale, as standard of care therapies?\n\nParticipants will receive 4 doses of efgartigimod over the course of 4 weeks with an additional follow-up visit at the clinic.",[29,31,37],[86,87],"myasthenia exacerbation","efgartigimod","2025-07-10",{"date":90,"type":62},"2025-07-11",{"date":92,"type":62},"2025-03-06",{"date":94,"type":21},"2026-12-31",{"name":96,"class":69},"University of Colorado, Denver"]